BiGART 2025 – the 25th Acta Oncologica Symposium

Grau C, Høyer M, Lindegaard J, Overgaard J. The emerging evidence for Stereotactic Body Radiotherapy. Acta Oncol. 2006;45:771–4.

https://doi.org/10.1080/02841860600943290 DOI: https://doi.org/10.1080/02841860600943290

Grau C, Muren LP, Høyer M, Lindegaard J, Overgaard J. Image-guided adaptive radiotherapy – integration of biology and technology to improve clinical outcome. Acta Oncol. 2008;47:1182–5.

https://doi.org/10.1080/02841860802282802 DOI: https://doi.org/10.1080/02841860802282802

Grau C, Olsen DR, Overgaard J, Høyer M, Lindegaard JC, Muren LP. Biology-guided adaptive radiation therapy – presence or future? Acta Oncol. 2010;49:884–7.

https://doi.org/10.3109/0284186X.2010.516010 DOI: https://doi.org/10.3109/0284186X.2010.516010

Grau C, Høyer M, Alber M, Overgaard J, Lindegaard JC, Muren LP. Biology-guided adaptive radiotherapy (BiGART) – more than a vision? Acta Oncol. 2013;52:1243–7.

https://doi.org/10.3109/0284186X.2013.829245 DOI: https://doi.org/10.3109/0284186X.2013.829245

Grau C, Overgaard J, Høyer M, Tanderup K, Lindegaard JC, Muren LP. Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. Acta Oncol. 2015;54:1245–50.

https://doi.org/10.3109/0284186X.2015.1076992 DOI: https://doi.org/10.3109/0284186X.2015.1076992

Grau C, Høyer M, Poulsen PR, Muren LP, Korreman SS, Tanderup K, et al. Rethink radiotherapy – BIGART 2017. Acta Oncol. 2017;56:1341–52.

https://doi.org/10.1080/0284186X.2017.1371326 DOI: https://doi.org/10.1080/0284186X.2017.1371326

Overgaard J, Muren LP, Høyer M, Grau C. BIGART 2019 – adapting to the future. Acta Oncol. 2019;58:1323–7.

https://doi.org/10.1080/0284186X.2019.1657587 DOI: https://doi.org/10.1080/0284186X.2019.1657587

Høyer M, Grau C, Overgaard J. No time to die – BiGART is back. The 20th Acta Oncologica Symposium – BIGART 2021. Acta Oncol. 2022;61:117–9.

https://doi.org/10.1080/0284186X.2021.2022206 DOI: https://doi.org/10.1080/0284186X.2021.2022206

Eriksen JG, Vrou Offersen B, Høyer M, Grau C, Overgaard J. Think big-think BiGART. The 21st Acta Oncologica Symposium-BiGART 2023. Acta Oncol. 2023;62:1357–9.

https://doi.org/10.1080/0284186X.2023.2263149 DOI: https://doi.org/10.1080/0284186X.2023.2263149

Lilja-Fischer J, Horsholt Kristensen M, Lassen P, Steiniche T, Tramm T, Stougaard M, et al. Mutational profile of oropharyngeal squamous cell carcinoma in relation to HPV, tobacco smoking and prognosis with validation in the DAHANCA 19 randomized trial. Acta Oncol. 2025;64:1129–35.

https://doi.org/10.2340/1651-226X.2025.44042 DOI: https://doi.org/10.2340/1651-226X.2025.44042

Toustrup K, Sørensen BS, Metwally MA, Tramm T, Mortensen LS, Overgaard J, et al. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncol. 2016;55:1091–8.

https://doi.org/10.3109/0284186X.2016.1167959 DOI: https://doi.org/10.3109/0284186X.2016.1167959

Spindler KG, Jakobsen AV, Eriksen JG, Fokdal L, Nordsmark M, Thorsen LBJ, et al. The clinical utility of circulating human papillomavirus across squamous cell carcinomas. Acta Oncol. 2025;64:1–12.

https://doi.org/10.2340/1651-226X.2025.41288 DOI: https://doi.org/10.2340/1651-226X.2025.41288

Bøje CR, Dalton SO, Grønborg TK, Primdahl H, Kristensen CA, Andersen E, et al. The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. Acta Oncol. 2013;52:285–93.

https://doi.org/10.3109/0284186X.2012.742964 DOI: https://doi.org/10.3109/0284186X.2012.742964

Lønbro S, Dalgas U, Primdahl H, Johansen J, Nielsen JL, Overgaard J, et al. Lean body mass and muscle function in head and neck cancer patients and healthy individuals – results from the DAHANCA 25 study. Acta Oncol. 2013;52:1543–51.

https://doi.org/10.3109/0284186X.2013.822553 DOI: https://doi.org/10.3109/0284186X.2013.822553

Halgren Olsen M, Maltesen T, Lassen P, Kjaer TK, Johansen J, Primdahl H, et al. Socioeconomic position and the pre-diagnostic interval among patients diagnosed with head and neck squamous cell carcinoma – a population-based study from DAHANCA. Acta Oncol. 2023;62:1394–402.

https://doi.org/10.1080/0284186X.2023.2254478 DOI: https://doi.org/10.1080/0284186X.2023.2254478

Petkar I. De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer. Lancet Oncol. 2025;26:1127–9.

https://doi.org/10.1016/S1470-2045(25)00408-5 DOI: https://doi.org/10.1016/S1470-2045(25)00408-5

Offersen BV, Overgaard J. Breast cancer radiation therapy. Lancet. 2020;396(10262):1558.

https://doi.org/10.1016/S0140-6736(20)32322-9 DOI: https://doi.org/10.1016/S0140-6736(20)32322-9

Petit C, Lacas B, Pignon JP, Le QT, Grégoire V, Grau C, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021;22:727–36.

https://doi.org/10.1016/S1470-2045(21)00076-0 DOI: https://doi.org/10.1016/S1470-2045(21)00076-0

Overgaard J, Larsson L-G. Fractionation in radiotherapy. Acta Oncol. 1988, 27: 81.

https://doi.org/10.3109/02841868809090327 DOI: https://doi.org/10.3109/02841868809090327

Saksø M, Andersen E, Bentzen J, Andersen M, Johansen J, Primdahl H, et al. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta Oncol. 2019;58:1495–501.

https://doi.org/10.1080/0284186X.2019.1658897 DOI: https://doi.org/10.1080/0284186X.2019.1658897

Evensen JF, Sand Hansen H, Overgaard M, Johansen J, Andersen LJ, Overgaard J. DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). Acta Oncol. 2019;58:1502–5.

https://doi.org/10.1080/0284186X.2019.1629012 DOI: https://doi.org/10.1080/0284186X.2019.1629012

Grau C, Defourny N, Malicki J, Dunscombe P, Borras JM, Coffey M, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:155–64.

https://doi.org/10.1016/j.radonc.2014.08.029 DOI: https://doi.org/10.1016/j.radonc.2014.08.029

Mälkiä T, Koivunoro H, Seppälä T, Kankaanranta L, Porra L, Anttonen A, et al. Predictive factors of oral mucositis in patients with locally recurrent inoperable head and neck cancer treated with boron neutron capture therapy. Acta Oncol. 2025;64:1307–11.

https://doi.org/10.2340/1651-226X.2025.44039 DOI: https://doi.org/10.2340/1651-226X.2025.44039

Wiik BH. Rolf Wideröe and the development of particle accelerators. Acta Oncol. 1998;37:615–25.

https://doi.org/10.1080/028418698430322 DOI: https://doi.org/10.1080/028418698430322

Svensson H, Jonsson L, Larsson LG, Brahme A, Lindberg B, Reistad D. A 22 MeV microtron for radiation therapy. Acta Radiol Ther Phys Biol. 1977;16:145–56.

https://doi.org/10.3109/02841867709134308 DOI: https://doi.org/10.3109/02841867709134308

Brahme A. Design principles and clinical possibilities with a new generation of radiation therapy equipment. A review. Acta Oncol. 1987;26:403–12.

https://doi.org/10.3109/02841868709113708 DOI: https://doi.org/10.3109/02841868709113708

Dahlin H, Lamm IL, Landberg T, Levernes S, Ulsø N. User requirements on CT-based computed dose planning systems in radiation therapy. Acta Radiol Oncol. 1983;22:397–415.

https://doi.org/10.3109/02841868309134059 DOI: https://doi.org/10.3109/02841868309134059

Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33:677–83.

https://doi.org/10.3109/02841869409121782 DOI: https://doi.org/10.3109/02841869409121782

Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861–70.

https://doi.org/10.3109/02841869509127197 DOI: https://doi.org/10.3109/02841869509127197

Aggarwal A, Lewison G, Rodin D, Zietman A, Sullivan R, Lievens Y. Radiation therapy research: a global analysis 2001–2015. Int J Radiat Oncol Biol Phys. 2018;101:767–78.

https://doi.org/10.1016/j.ijrobp.2018.03.009 DOI: https://doi.org/10.1016/j.ijrobp.2018.03.009

Grossi F, Belvedere O, Rosso R. Geography of clinical cancer research publications from 1995 to 1999. Eur J Cancer. 2003;39:106–11.

https://doi.org/10.1016/s0959-8049(02)00239-3 DOI: https://doi.org/10.1016/S0959-8049(02)00239-3

Ejlertsen B, Offersen BV, Overgaard J, Christiansen P, Jensen MB, Kroman N, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2018;57:3–12.

https://doi.org/10.1080/0284186X.2017.1408962 DOI: https://doi.org/10.1080/0284186X.2017.1408962

Ringborg U, Bergqvist D, Brorsson B, Cavallin-Ståhl E, Ceberg J, Einhorn N, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001 – summary and conclusions. Acta Oncol. 2003;42:357–65.

https://doi.org/10.1080/02841860310010826 DOI: https://doi.org/10.1080/02841860310010826

Möller TR, Einhorn N, Lindholm C, Ringborg U, Svensson H. Radiotherapy and cancer care in Sweden. Acta Oncol. 2003;42:366–75.

https://doi.org/10.1080/02841860310010817 DOI: https://doi.org/10.1080/02841860310010817

Overgaard J. Management of the axilla in breast cancer. implication for diagnosis, prognosis, treatment, and morbidity. Acta Oncol. 2000;39:259–60.

https://doi.org/10.1080/028418600750012970 DOI: https://doi.org/10.1080/028418600750012970

Forssell G. Editorial. Acta Radiol. 1921;1:1–4.

https://doi.org/10.3109/00016922109133326 DOI: https://doi.org/10.3109/00016922109133326